Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational studyAnne Murarasu, C. Bélizna, Estibaliz Lazaro et al.|The Lancet Rheumatology|2022Cited by 24
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trialStéphane Zuily, Emmanuel Oger, Benjamin Lefèvre et al.|EClinicalMedicine|2023Cited by 16
CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND POSTERIOR OCULAR INVOLVEMENTNathalie Morel, N. Costedoat‐Chalumeau, Clémence Bonnet et al.|Retina|2021Cited by 13
Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)Cécile Yelnik, Doruk Erkan, Zeynep Belce Erton et al.|Seminars in Arthritis and Rheumatism|2023Cited by 7
Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective studyAnne Murarasu, Claire Blanchard‐Delaunay, Lauren Beaudeau et al.|The Lancet Rheumatology|2025Cited by 4